Von Hippel-Lindau Tumor Suppressor Protein
"Von Hippel-Lindau Tumor Suppressor Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.
Descriptor ID |
D051794
|
MeSH Number(s) |
D08.811.464.938.750.875 D12.776.624.776.865
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Von Hippel-Lindau Tumor Suppressor Protein".
Below are MeSH descriptors whose meaning is more specific than "Von Hippel-Lindau Tumor Suppressor Protein".
This graph shows the total number of publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in this website by year, and whether "Von Hippel-Lindau Tumor Suppressor Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 2 | 2 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2002 | 0 | 2 | 2 |
2003 | 0 | 4 | 4 |
2004 | 0 | 2 | 2 |
2005 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2007 | 0 | 3 | 3 |
2008 | 3 | 1 | 4 |
2009 | 1 | 1 | 2 |
2010 | 0 | 2 | 2 |
2011 | 1 | 2 | 3 |
2012 | 4 | 1 | 5 |
2013 | 1 | 2 | 3 |
2014 | 3 | 2 | 5 |
2015 | 0 | 1 | 1 |
2016 | 2 | 1 | 3 |
2017 | 4 | 2 | 6 |
2018 | 1 | 1 | 2 |
2019 | 2 | 2 | 4 |
2020 | 2 | 3 | 5 |
2021 | 1 | 4 | 5 |
2022 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in Profiles.
-
Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940.
-
Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clin Genitourin Cancer. 2023 04; 21(2):238-247.
-
VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions. Front Endocrinol (Lausanne). 2022; 13:854365.
-
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.
-
Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci Rep. 2021 05 17; 11(1):10461.
-
Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 05; 27(5):802-805.
-
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021 04 01; 131(7).
-
Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci. 2021 Mar 11; 22(6).
-
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders. J Med Chem. 2020 09 10; 63(17):9977-9989.
-
The Daam2-VHL-Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation. Genes Dev. 2020 09 01; 34(17-18):1177-1189.